We have helped to secure more than $80 billion in jury verdicts and settlements since 1955.
Our Ozempic lawsuit lawyers are investigating cases where individuals have suffered gastroparesis/stomach paralysis (“frozen stomach”) after using the weight loss drugs Ozempic, Wegovy, or Rybelsus because the manufacturer of these drugs failed to adequately warn patients and doctors of the risk of these dangerous gastrointestinal side effects.
Levin Papantonio has been handling lawsuits against drug manufacturers since 1955. Our firm is listed in Best Lawyers in America and The National Trial Lawyers Hall of Fame. You can trust us to handle your Ozempic/Wegovy/Rybelsus lawsuit for gastroparesis/stomach paralysis.
If you or a loved one took a GLP-1 RA like Ozempic and received a gastroparesis (stomach paralysis) or gastric obstruction, call us today for a free, no-obligation case evaluation. Call (800) 277-1193 or complete a short Free Evaluation Form.
Our law firm is dedicated to offering victims the latest updates on Ozempic lawsuits. We frequently update this page to ensure you have the most current news and information relevant to your claim.
Around mid-March, Eli Lilly started pushing for stricter gastroparesis diagnosis standard in GLP-1RA lawsuits. Eli Lilly is asking the court to require that a gastroparesis diagnosis be based on objective medical testing. Their motion also seeks to block testimony from plaintiffs’ experts who argue that a diagnosis can still be reliable without such testing.
While objective testing can help, doctors often rely on symptoms, medical history, and clinical judgment—especially when tests are inconclusive or unavailable. By pushing for a stricter standard, Eli Lilly is trying to limit the number of valid claims against them. This isn’t about medical accuracy—it’s a legal strategy to weaken plaintiffs’ cases and avoid accountability.
Toward the end of last month, the Honorable Karen Spencer Marson entered an order specifying the dates for status conferences in the GLIP-1RA MDL. A status conference is scheduled to take place March 18.
A study published January 30, 2025, found that medications like Ozempic and Mounjaro, commonly used to treat diabetes and aid in weight loss, may be linked to rare eye conditions that can cause vision loss or even blindness.
A review published in JAMA Ophthalmology detailed nine cases where patients experienced significant vision problems after taking these drugs. The conditions seen include non-arteritic anterior ischemic optic neuropathy (NAION). This condition causes sudden vision loss from reduced blood flow to the optic nerve.
The number of lawsuits against GLP-1 drugmakers has now reached 1,443. More than 100 new cases were added in early February.
One of the latest filings is a lawsuit from a woman in Michigan. She claims that Ozempic caused her serious stomach problems. These issues required her to go to the hospital. Plaintiffs say that Novo Nordisk and other companies did not give enough warnings about these risks. They claim these companies marketed GLP-1 drugs as safe and effective for weight loss. The litigation is moving forward.
The next status conference is set for February 24. During this meeting, attorneys will talk about the case’s progress and the next steps.
The lawsuits against GLP-1 drug makers, like Novo Nordisk (Ozempic), are increasing. As of early January, there are 1,331 lawsuits pending. Plaintiffs claim these medications caused severe gastrointestinal disorders, liver and pancreas damage, and other serious health complications. A key event this month is the scheduling of a hearing on May 14, 2025. During this hearing, the judge will decide if expert testimony for the plaintiffs’ claims can be used in court. This decision could greatly affect the case’s direction. Thecourt chose not to include deep vein thrombosis (DVT) in the current MDL. They also decided not to include NAION, which is a type of vision loss. This may lead to a new MDL that focuses on these conditions.
The U.S. Food and Drug Administration (FDA) has added a new warning to the weight-loss medication Wegovy, highlighting potential gastrointestinal reactions and stressing that individuals with severe gastroparesis should not take Wegovy. This update follows reports of adverse effects such as nausea, vomiting, and abdominal pain among users. Healthcare providers are advised to monitor patients for these symptoms and consider discontinuing the medication if severe reactions occur.
As of November 1, the total number of pending cases in the Ozempic, Wegovy, Rybelsus MDL is 1,221.
The month started with 101 new cases that were added to the multidistrict litigation during September. According to the JPML, 1,090 cases are now pending in the GLIP-1RA MDL .
Early discovery and motion practice has been scheduled on two issues: preemption (whether federal law overrides the case) and whether warning labels were clear enough. The plaintiffs are asking to include marketing discovery early, arguing that it’s crucial because drug companies often downplay risks in their marketing, which could impact the case.
Earlier this month, CBS News reported on a lawsuit a woman filed against the makers of popular weight-loss drugs Ozempic and Mounjaro, claiming the companies failed to adequately warn about the risk of severe gastrointestinal issues. The plaintiff alleges she suffered from severe vomiting, stomach pain, and gastroparesis, or paralysis of the stomach, after using the drugs. [CBS News]
The month of August ended with a total of 869 pending lawsuits in the GLP-1RA Products Liability Litigation MDL.
On July 14, 2024, the Hon. Karen Spencer Marston entered several case management orders (CMOs) in the GLP-1RAs Product Liability MDL.
The Judicial Panel on Multidistrict Litigation has reassigned the Ozempic GLP-1RA MDL docket, which involves lawsuits claiming injuries from drugs like Ozempic and Mounjaro, to Judge Karen S. Marston. This change happened after Judge Gene E.K. Pratter passed away.
Judge Pratter, who was 75 years old, served in the U.S. District Court for the Eastern District of Pennsylvania. She died from chronic lung disease on May 17 at the Hospital of the University of Pennsylvania, as reported by The Philadelphia Inquirer.
As of May 1, 2024, the Judicial Panel on Multidistrict Litigation (JPML) reports 87 cases are pending in MDL -3094 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation.
On May 8, 2024, U.S. District Judge Gene E.K. Pratter issued Case Management Order No. 6, which expanded the Leadership Structure for the Ozempic lawsuits [IN RE: GLUGAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION (MDL 3094)]. Levin Papantonio Rafferty (LPR) Attorney Cameron Stephenson was appointed to the Plaintiffs’ Executive Committee in this MDL.
The first status conference for the Ozempic multidistrict litigation occurred last week, gathering attorneys from Novo Nordisk and plaintiffs who have either filed cases or are seeking positions in the plaintiffs’ attorney leadership group for the MDL. This initial case management meeting was conducted in a federal court in Pennsylvania.
In February 2024, the Judicial Panel on Multidistrict Litigation (JPML) established MDL No. 3094, issuing a Transfer Order to centralize lawsuits claiming that the manufacturers of GLP-1 RA weight-loss drugs, such as Ozempic, Wegovy, and Rybelsus, did not adequately warn patients and doctors about the risk of severe gastrointestinal side effects.
Fifty-five ongoing actions and future related cases were moved to the Eastern District of Pennsylvania for consolidated pretrial proceedings, with the MDL assigned to the Honorable Gene E.K. Pratter.
CNN wrote about the problems some users of these diabetes drugs are experiencing and reported that doctors are coming forward with reports of gastroparesis/stomach paralysis from patients who took these weight-loss medications.
The U.S. Food and Drug Administration (FDA) has received adverse event reports of gastroparesis/stomach paralysis from individuals who took the GLP-1 Receptor Agonists (RA) drugs.
The first such GLP-1 RA drug lawsuit filed involved a woman who began receiving Ozempic injections in the spring of 2022. According to the plaintiff, within two years’ time, she was suffering from severe stomach paralysis. Switching to another medication, Mounjaro, did not alleviate her symptoms.
Novo Nordisk, the maker of these weight-loss drugs, does not include warnings about the increased risk of gastroparesis/stomach paralysis (“frozen stomach”) for people who consume the medications or receive GLP-1 RA treatments.
The compensation you could recover in a verdict or settlement in these semaglutide gastroparesis/stomach paralysis lawsuits depends on the type and extent of your injuries. Generally, a settlement in this type of case could cover several types of damages, including (but not limited to):
Our attorneys will fight to get you the maximum financial compensation to cover the losses you have suffered from gastroparesis/stomach paralysis after taking Ozempic, Wegovy, or Rybelsus diabetes weight loss drugs.
Ozempic, Wegovy, and Rybelsus belong to a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RA). All three drugs share the same common active ingredient: semaglutide.
The Semaglutide Class
Semaglutide is a class of prescription drug used to control high blood sugar in individuals with type 2 diabetes mellitus. It is classified as a GLP-1 Receptor Agonist Analog-Type drug. The medication mimics a natural human glucagon-like peptide (GLP-1) to slow the passing of food through the stomach.
How the Weight-Loss Drugs Differ
Patients receive Ozempic and Wegovy as a subcutaneous injection. The key difference between the two drugs is that Ozempic is designed for treatment of type 2 diabetes at doses of 0.5 to 1 mg weekly, while Wegovy has been FDA-approved as a weight loss drug with a weekly dosage of 2.4 mg. Like Ozempic, Rybelsus is designed to treat type 2 diabetes mellitus, but the patient takes this medication daily in the form of an oral tablet.
Our law firm is currently investigating cases on behalf of individuals who received Ozempic, Wegovy, or Rybelsus Brand Name (no generics or compounds) treatments (in pills or via injections) and:
Our law firm is currently investigating cases on behalf of individuals who received Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, Zepbound Brand Name (no generics or compounds) treatments (in pills or via injections) and:
The primary legal issue could be whether the Ozempic, Wegovy, and Rybelsus manufacturer Novo Nordisk knew or should have known about the heightened risks for gastroparesis/stomach paralysis that these drugs posed to users and failed to warn doctors and patients of this risk.
If you or a loved one took a GLP-1 RA such as Ozempic and suffered from gastroparesis (stomach paralysis) or gastric obstruction, contact us today for a free, no-obligation case evaluation. Call us at (800) 277-1193 or fill out our brief Free Evaluation Form.
Gastroparesis is a medical condition in which the patient’s stomach does not empty properly. According to Mayo Clinic, strong muscles in a healthy stomach contract to move food through the digestive tract. The motility in a patient with gastroparesis, however, slows down. In some cases, the muscles do not work at all.
As a result, the patient’s stomach does not empty—or fails to empty to the extent it should—meaning food stays in the stomach longer than it should, rather than moving on for digestion in the small intestine.
A study published in 2009 issue of Gastroenterology scientific journal reported only one in 100,000 people have gastroparesis (Jung HK, Choung RS, Locke GR III, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136(4):1225–1233.).
Gastroparesis can negatively impact a patient’s blood sugar levels and nutrition. The condition can also impede healthy digestion. Symptoms of gastroparesis include:
There is no cure for gastroparesis. Treatments for the condition appear to offer only temporary benefits, according to MedlinePlus, the authoritative source that gathers health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.
The National Institute of Diabetes and Digestive and Kidney Diseases lists a range of complications that can arise from gastroparesis:
The below studies constitute a small sampling of the scientific literature and studies published on the diabetes weight-loss drugs and gastroparesis/stomach paralysis:
This was a small clinical trial of 20 obese female patients with polycystic ovary syndrome who were given semaglutide or placebo. From baseline to the study end, semaglutide increased subjects’ estimated retention of gastric contents after eating radioactively labelled solid meals as follows:
The time it took for half the radiolabeled meal to empty from the stomach was significantly longer in the semaglutide group than the placebo group (171 vs. 118 min; P less than 0.001).
In this retrospective chart review, GLP-1 RA use was associated with delayed gastric emptying in patients who had diabetes for less than 10 years. Twenty-four percent of patients with diabetes with delayed gastric emptying were taking a GLP-1 RA.
This case report detailed retained food in the stomach of a patient taking semaglutide despite following preoperative fasting guidelines, resulting in intraoperative pulmonary aspiration.
This research involved the study of 100 patients who underwent routine gastroscopy before sleeve gastrectomy. Four out of 23 patients on GLP-1 RAs manifested bezoars, compared with 0 out of 77 of the patients who were not on GLP-1 RAs. One to three weeks after the GLP-1 RA therapy was stopped, the delayed emptying of the stomach and bezoars resolved.
Twenty patients were given semaglutide or a control, with the following results after an 8-hour fasting period:
Have you or a loved one taken a GLP-1 RA like Ozempic and been diagnosed with gastroparesis (stomach paralysis) or gastric obstruction? Reach out to us today for a complimentary case evaluation with no obligation. Call (800) 277-1193 or complete our short Free Evaluation Form.
By selecting "I Agree" below and clicking the "Submit for Free Evaluation” button, I agree to the POLICIES AND DISCLAIMERS, including arbitration provision therein, and consent to receive marketing emails, calls and/or texts, including those made using an automated system and/or artificial/prerecorded voice message, from or on behalf of Levin Papantonio Law Firm (“LP”) / Pensacola, FL / 850-435-7000 / levinlaw.com, regarding their services in response to my inquiry at the telephone number(s) provided above, even if that number is currently listed on any state, federal or corporate Do Not Call registry. I understand my consent to receive automated marketing calls/texts is not required as a condition of purchasing any services. I can revoke my consent at any time. Review LP's Terms and Conditions and Privacy Policy here.
Opt in to Receive Calls, Text Messages, and Emails
By checking the below box and clicking “SUBMIT”, I agree to the Terms of the Policies and Procedures of the referenced entity, including individual arbitration provisions therein. I also consent to receive marketing emails, calls, and/or text messages, including those made using an automated system and/or artificial/prerecorded voice message (including artificial intelligence (AI)-generated voices), from or on behalf of the referenced entity regarding its services and/or my inquiry at the telephone number provided above, even if currently listed on any state or federal Do Not Call registry. I understand that my consent to receive automated marketing calls/texts is not required as a condition of purchasing any services, and that I may opt out of such calls/texts at any time.
Levin Law